Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 11;170(1):96-103.
doi: 10.1001/archinternmed.2009.456.

Impact of FDA black box advisory on antipsychotic medication use

E Ray Dorsey  1 , Atonu Rabbani, Sarah A Gallagher, Rena M Conti, G Caleb Alexander
Affiliations

Impact of FDA black box advisory on antipsychotic medication use

E Ray Dorsey et al. Arch Intern Med. .

Abstract

Background: In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical anti psychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown.

Methods: We used quasi-experimental, interrupted time-series analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia.

Results: From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia. In 2004, 19% (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9% (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined.

Conclusion: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in monthly atypical antipsychotic use, 2003–2008. The dashed line shows 6-month moving average; source: IMS Health National Disease and Therapeutic Index. FDA indicates Food and Drug Administration.
Figure 2
Figure 2
Joinpoint Regression Program analysis for atypical antipsychotics use among elderly patients with dementia. The data points represent patients 65 years and older with dementia (smoothed 6-month averages); the solid line, fitted joinpoint time series.
Figure 3
Figure 3
Proportion of drug uses that were atypical antipsychotics among individuals with dementia, stratified by visit location, 2003–2008.
See this image and copyright information in PMC

Comment in

References

    1. Risperdal: full US prescribing information. http://www.risperdal.com/risperdal/prescribing.html. Accessed August 15, 2009.
    1. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703–1711. - PMC - PubMed
    1. Food and Drug Administration. Risperdal (risperidone) 2003 Apr; http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma.... Accessed August 15, 2009.
    1. Food and Drug Administration. Zyprexa (olanzapine) 2004 Mar; http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma.... Accessed August 15, 2009.
    1. Food and Drug Administration. Atypical antipsychotic drugs. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma.... Accessed August 15, 2009.

Publication types

Substances